keyword
MENU ▼
Read by QxMD icon Read
search

Oral agentes antidiabetes

keyword
https://www.readbyqxmd.com/read/28207538/comparison-of-baseline-characteristics-and-clinical-course-in-japanese-patients-with-type-2-diabetes-among-whom-different-types-of-oral-hypoglycemic-agents-were-chosen-by-diabetes-specialists-as-initial-monotherapy-jddm-42
#1
Kazuya Fujihara, Risa Igarashi, Satoshi Matsunaga, Yasuhiro Matsubayashi, Takaho Yamada, Hiroki Yokoyama, Shiro Tanaka, Hitoshi Shimano, Hiroshi Maegawa, Katsuya Yamazaki, Koichi Kawai, Hirohito Sone
Little is known about the relationships between patient factors and the antihyperglycemic agents that have been prescribed as initial therapy by diabetes specialists for patients with type 2 diabetes. Moreover, there has been little clarification of the subsequent usage patterns and related factors that influenced the continuation or discontinuation of the drug or the addition of another drug. To provide information on these issues, we evaluated the clinical characteristics of Japanese patients with type 2 diabetes for whom different types of oral hypoglycemic agents (i...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28166431/change-of-hba1c-associated-with-treatment-intensification-among-patients-with-type-2-diabetes-and-poor-glycemic-control
#2
Alex Z Fu, John J Sheehan
OBJECTIVE: We conducted a retrospective cohort study to investigate the HbA1c change associated with treatment intensification in a real-world population of patients with type 2 diabetes (T2D). METHODS: Using a large U.S. insurance claims database, patients aged ≥18 years with a T2D diagnosis and HbA1c ≥8.0% (64 mmol/mol) after ≥3 months of oral pharmacotherapy with metformin (± other oral antidiabetes agents) were identified (index date). Continuous enrollment was required for ≥12 months before (baseline) and after the index date with no baseline use of injectable antidiabetes drugs...
February 6, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28151905/impact-of-patient-and-treatment-characteristics-on-glycemic-control-and-hypoglycemia-in-patients-with-type-2-diabetes-initiated-to-insulin-glargine-or-nph-a-post-hoc-pooled-patient-level-analysis-of-6-randomized-controlled-trials
#3
Francesca Porcellati, Jay Lin, Paola Lucidi, Geremia B Bolli, Carmine G Fanelli
BACKGROUND: The goal of this post hoc analysis was to determine key patient and treatment-related factors impacting glycosylated hemoglobin (A1C) and hypoglycemia in patients with uncontrolled type 2 diabetes who were initiated to basal insulin (neutral protamine Hagedorn [NPH] or glargine). METHODS: Using individual patient-level data pooled from 6 treat-to-target trials, 2600 patients with type 2 diabetes on oral antidiabetic agents initiated to insulin glargine or NPH and treated for 24 to 36 weeks were analyzed...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28126469/antidiabetic-medications-use-trends-in-an-andalusian-region-from-2001-to-2014
#4
Rocío López-Sepúlveda, María Ángeles García Lirola, Esther Espínola García, Jose María Jurado Martínez, Salvadora Martín Sances, Sonia Anaya Ordóñez, José Cabeza Barrera
PURPOSE: There is a widening range of antidiabetic medications available; however changes in consumption patterns remain poorly documented. The aim of this study is to analyze the evolution of consumption of antidiabetic medications during the period 2001-2014 in an Andalusian region. METHODS: All antidiabetic medicines on the market were selected for analysis. Consumption data were obtained for the 15-year period and were expressed in defined daily doses (DDD) per 1000 inhabitants per day (DHD)...
January 23, 2017: Primary Care Diabetes
https://www.readbyqxmd.com/read/28115226/dual-crosslinked-pectin-alginate-network-as-sustained-release-hydrophilic-matrix-for-repaglinide
#5
Rajendra Awasthi, Giriraj T Kulkarni, Malipeddi Venkata Ramana, Terezinha de Jesus Andreoli Pinto, Irene Satiko Kikuchi, Daniela Dal Molim Ghisleni, Marina de Souza Braga, Paul De Bank, Kamal Dua
Repaglinide, an oral antidiabetic agent, has a rapid onset of action and short half-life of approximately 1h. Developing a controlled and prolonged release delivery system is required to maintain its therapeutic plasma concentration and to eliminate its adverse effects particularly hypoglycemia. The present study aimed to develop controlled release repaglinide loaded beads using sodium alginate and pectin with dual cross-linking for effective control of drug release. The prepared beads were characterized for size, percentage drug entrapment efficiency, in vitro drug release and the morphological examination using scanning electron microscope...
April 2017: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/28073124/the-effects-of-blood-glucose-regulation-in-omentin-1-levels-among-diabetic-patients
#6
Yucel Arman, Kerem Kirna, Bilal Ugurlukisi, Orkide Kutlu, Okan Dikker, Eylem Ozgun Cil, Murat Akarsu, Mustafa Ozcan, Gulden Yuruyen, Pinar Demir, Ozgur Altun, Ekmel Burak Ozsenel, Mustafa Genco Erdem, Riza Sandikci, Tufan Tukek
Objectives: Omentin-1, an adipocytokine that increases the insulin sensitivity, has been determined to be reduced in patients with insulin resistance, impaired glucose tolerance, and Type-2 diabetes mellitus. In this study, we have investigated the alterations in Omentin-1 levels with the blood glucose regulation in diabetic patients having poor glycemic control. By this way, we aimed to determine the role of Omentin-1 as a marker in follow-up and monitoring progression of diabetes. Methods: Totally 58 patients with type 2 diabetes mellitus, older than 18 years of age who were having poor glycemic control (HbA1c≥9) were included in this study...
January 10, 2017: Experimental and Clinical Endocrinology & Diabetes
https://www.readbyqxmd.com/read/28065677/multistrategic-approach-to-improve-quality-of-care-of-people-with-diabetes-at-the-primary-care-level-study-design-and-baseline-data
#7
Mariana Prestes, María Angelica Gayarre, Jorge Federico Elgart, Lorena Gonzalez, Enzo Rucci, Juan José Gagliardino
AIM: To test the one year-post effect of an integrated diabetes care program that includes system changes, education, registry (clinical, metabolic and therapeutic indicators) and disease management (DIAPREM), implemented at primary care level, on care outcomes and costs. METHODS: We randomly selected 15 physicians and 15 nurses from primary care units of La Matanza County to be trained (Intervention-IG) and another 15 physicians/nurses to use as controls (Control-CG)...
January 5, 2017: Primary Care Diabetes
https://www.readbyqxmd.com/read/28045450/agrimoniin-an-active-ellagitannin-from-comarum-palustre-herb-with-anti-%C3%AE-glucosidase-and-antidiabetic-potential-in-streptozotocin-induced-diabetic-rats
#8
Nina I Kashchenko, Nadezhda K Chirikova, Daniil N Olennikov
Naturally existing α-glucosidase inhibitors from traditional herbal medicines have attracted considerable interest to treat type 2 diabetes mellitus (DM). The present study aimed to evaluate the anti-α-glucosidase activity of extracts from marsh cinquefoil (Comarum palustre L.), their hypoglycaemic action and detection of the responsible compounds. A 60% ethanol extract from C. palustre herb revealed the highest inhibitory activity against α-glucosidase (IC50 52.0 μg/mL). The HPLC analysis of the major compounds resulted in detection of 15 compounds, including ellagitannins, flavonoids, catechin and other compounds...
January 2, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/27943107/the-efficacy-of-ideglira-insulin-degludec-liraglutide-combination-in-adults-with-type-2-diabetes-inadequately-controlled-with-a-glp-1-receptor-agonist-and-oral-therapy-dual-iii-randomized-clinical-trial
#9
Sultan Linjawi, Bruce W Bode, Louis B Chaykin, Jean-Pierre Courrèges, Yehuda Handelsman, Lucine M Lehmann, Abhishek Mishra, Richard W Simpson
INTRODUCTION: The progressive nature of type 2 diabetes necessitates treatment intensification. This often involves intensification with oral antidiabetic drugs (OADs) initially, followed by other agents, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), with the majority of patients eventually requiring insulin therapy. Therefore, this trial aimed to investigate the efficacy of IDegLira (combination of insulin degludec and liraglutide) in controlling glycemia in adults with type 2 diabetes who were inadequately controlled on a GLP-1RA and OADs...
February 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27936468/rosiglitazone-reduces-breast-cancer-risk-in-taiwanese-female-patients-with-type-2-diabetes-mellitus
#10
Chin-Hsiao Tseng
This study investigated whether rosiglitazone may affect breast cancer risk in female patients with type 2 diabetes mellitus in Taiwan. The reimbursement database of all female patients with type 2 diabetes mellitus under oral antidiabetic agents or insulin from 1996 to 2009 was retrieved from the National Health Insurance. An entry date was set on 1 January 2006 and a total of 431447 patients were followed up for breast cancer incidence till the end of 2009. Incidences for ever users, never users and subgroups of rosiglitazone dose-response parameters (tertile cutoffs of cumulative duration and cumulative dose) were calculated and hazard ratios estimated by Cox regression...
January 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/27928947/oral-glucose-lowering-drugs-and-cardiovascular-outcomes-from-the-negative-record-and-accord-to-neutral-tecos-and-promising-empa-reg
#11
C Tsioufis, E Andrikou, C Thomopoulos, N Papanas, D Tousoulis
Cardiovascular (CV) morbidity and mortality are higher among patients with diabetes mellitus type 2 (T2DM), particularly those with concomitant CV diseases, compared with other populations. In patients with T2DM, intensive glucose lowering reduces microvascular disease, but has a smaller and debated effect on CV events or mortality. In this setting, the US Food and Drug Administration (FDA) required in 2008 that all new agents for the treatment of T2DM should be evaluated in terms of CV safety. Metformin has long been established as first-line pharmacological therapy in patients with T2DM, due to its proven beneficial CV effects...
December 8, 2016: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/27866701/place-of-sodium-glucose-cotransporter-2-inhibitors-in-east-asian-subjects-with-type-2-diabetes-mellitus-insights-into-the-management-of-asian-phenotype
#12
REVIEW
Lee Ling Lim, Alexander Tong Boon Tan, Kevin Moses, Viraj Rajadhyaksha, Siew Pheng Chan
The burden of type 2 diabetes (T2DM) in East Asia is alarming. Rapid modernization and urbanization have led to major lifestyle changes and a tremendous increase in the prevalence of obesity, metabolic syndrome, and diabetes mellitus. The development of T2DM at a younger age, with lower body mass index, higher visceral adiposity, and more significant pancreatic beta-cell dysfunction compared to Caucasians are factors responsible for the increased prevalence of T2DM in East Asians. Sodium-glucose Cotransporter-2 (SGLT2) inhibitors (canagliflozin, dapaglifozin, empagliflozin, etc...
October 15, 2016: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/27853981/intensification-of-idegasp-twice-daily-adding-insulin-aspart-vs-switching-to-basal-bolus-exploratory-randomized-trial-in-type-2-diabetes
#13
Wan Mohamaed Wan Bebakar, Louis Chaykin, Malene Lundgren Hersløv, Søren Rasmussen
INTRODUCTION: In a preceding trial comparing two different titration schemes, insulin degludec/insulin aspart (IDegAsp) showed good efficacy for achieving HbA1c <7% when administered twice daily (BID) in patients with uncontrolled type 2 diabetes (T2D). However, poor glycemic control persisted in a minority of patients. The current exploratory trial investigated the efficacy and safety of intensifying IDegAsp BID treatment in these patients by either adding a once-daily (OD) bolus injection of insulin aspart (IAsp) or by switching to a basal-bolus regimen of insulin degludec (IDeg) plus IAsp taken three times a day (TID)...
February 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27832382/diabetes-diabetes-treatment-and-mammographic-density-in-danish-diet-cancer-and-health-cohort
#14
Karsten Buschard, Katrin Thomassen, Elsebeth Lynge, Ilse Vejborg, Anne Tjønneland, My von Euler-Chelpin, Zorana Jovanovic Andersen
PURPOSE: We examined whether diabetes and diabetes treatment are associated with MD in a cohort study of Danish women above age of 50 years. METHODS: Study cohort consisted of 5,644 women (4,500 postmenopausal) who participated in the Danish Diet, Cancer, and Health cohort (1993-1997) and subsequently attended mammographic screening in Copenhagen (1993-2001). We used MD assessed at the first screening after the cohort entry, defined as mixed/dense or fatty. Diabetes diagnoses and diabetes treatments (diet, insulin, or oral antidiabetic agents) were self-reported at the time of recruitment (1993-1997)...
January 2017: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/27824405/antidiabetic-and-antihyperalgesic-effects-of-a-decoction-and-compounds-from-acourtia-thurberi
#15
Ana Laura Martínez, Abraham Madariaga-Mazón, Isabel Rivero-Cruz, Robert Bye, Rachel Mata
The purpose of this research was to examine the preclinical efficacy of a decoction from the roots of Acourtia thurberi as a hypoglycemic, antihyperglycemic, and antihyperalgesic agent using well-known experimental models in mice. Acute oral administration of A. thurberi decoction did not produce toxic effects in mice, according to the Lorke procedure. A. thurberi decoction (31.6-316.2 mg/kg, p. o.) decreased blood glucose levels during acute hypoglycemic and the oral glucose tolerance and oral sucrose tolerance tests, both in normoglycemic and hyperglycemic animals...
November 4, 2016: Planta Medica
https://www.readbyqxmd.com/read/27766241/gemigliptin-an-update-of-its-clinical-use-in-the-management-of-type-2-diabetes-mellitus
#16
REVIEW
Sung-Ho Kim, Jung-Hwa Yoo, Woo Je Lee, Cheol-Young Park
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease glucagon secretion, and contribute to reducing postprandial hyperglycemia. Although DPP-4 inhibitors have similar benefits, they can be differentiated in terms of their chemical structure, pharmacology, efficacy and safety profiles, and clinical considerations. Gemigliptin (brand name: Zemiglo), developed by LG Life Sciences, is a potent, selective, competitive, and long acting DPP-4 inhibitor...
October 2016: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/27751591/selective-speciation-improves-efficacy-and-lowers-toxicity-of-platinum-anticancer-and-vanadium-antidiabetic-drugs
#17
Kaitlin A Doucette, Kelly N Hassell, Debbie C Crans
Improving efficacy and lowering resistance to metal-based drugs can be addressed by consideration of the coordination complex speciation and key reactions important to vanadium antidiabetic drugs or platinum anticancer drugs under biological conditions. The methods of analyses vary depending on the specific metal ion chemistry. The vanadium compounds interconvert readily, whereas the reactions of the platinum compounds are much slower and thus much easier to study. However, the vanadium species are readily differentiated due to vanadium complexes differing in color...
December 2016: Journal of Inorganic Biochemistry
https://www.readbyqxmd.com/read/27738482/comparison-of-combined-tofogliflozin-and-glargine-tofogliflozin-added-to-insulin-and-insulin-dose-increase-therapy-in-uncontrolled-type-2-diabetes
#18
Katsunori Suzuki, Yurie Mitsuma, Takaaki Sato, Takumi Anraku, Mariko Hatta
BACKGROUND: Some patients with type 2 diabetes mellitus (T2DM) on insulin have poor glycemic control and require add-on therapy to reach target glucose values. Increased insulin doses or the addition of an oral antidiabetic drug (OAD) may improve glycemic control, but many patients fail to achieve target values. The aim of this study was to compare the treatment efficacy and safety of three different therapies in such patients. METHODS: T2DM outpatients with poor glycemic control (HbA1c ≥ 7...
November 2016: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/27731814/ameliorative-potential-of-solanum-trilobatum-leaf-extract-and-fractions-on-lipid-profile-and-oxidative-stress-in-experimental-diabetes
#19
KhaderSyed Zameer Ahmed, Syed Zameer Ahmed Sidhra, Ponnusamy Ponmurugan, Balasubramanian Senthil Kumar
Solanum trilobatum Linn is a medicinal plants used in India from many centuries to cure various diseases. The purpose of the study is to evaluate the ameliorative potential of the ethanolic leaf extract and fractions of Solanum trilobatum (St) against alloxan induced diabetic rats. Solanum trilobatum leaf extract and fractions were administered orally at two different concentration (100-200mg/kg body weight) to alloxan induced diabetic rats. The antidiabetic efficacy was validated through various biochemical parameters, enzyme assays, renal markers and antioxidant properties were also determined...
September 2016: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/27676771/bilateral-proximal-femoral-agenesis-case-report
#20
Mouna Sghir, Mohamed Guedria, Marwa Maraoui, Wafa Haj Hamad, Wafa Said, Saida Jerbi, Wassia Kessomtini
OBJECTIVE: The femur aplasia is a congenital developmental defect of the femur often associated with malformations of the pelvis and lower limb. There are all intermediaries between the short femur and vestigial femoral. The total femur absence (agenesis) is rare. We report a case of a child followed in our Physical Medicine Department for proximal bilateral femoral agenesis. OBSERVATIONS: This is M.S., a 5 years old child, addressed for a waddling gait and a deformation of the trunk...
September 2016: Annals of Physical and Rehabilitation Medicine
keyword
keyword
72007
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"